Molecular Abnormalities in Ovarian Cancer Subtypes Other than High-Grade Serous Carcinoma
作者： C. Blake Gilks
DOI: 10.1155/2010/740968
关键词:
摘要: Ovarian cancer is the fifth leading cause of death in women North America, and approximately two-thirds cases ovarian are high-grade serous type. The remaining comprised a mix different tumor types (e.g., endometrioid, clear cell, mucinous, etc.), with no single type accounting for more than 10% cases. These can be reproducibly diagnosed, each features distinct underlying molecular events during oncogenesis, characteristic natural history response rate to conventional cytotoxic chemotherapy. In this review abnormalities present common non-high-grade subtypes will presented. Development targeted therapies these require understanding genetic basis type, may lead subtype-specific therapy.
hindawi.com参考文章(45)
Georgia Chenevix-Trench, Andrew Hitchcock, Eric J. Thomas, Sarah J. Morland, Ian G. Campbell, Richard H. Watson, Koshiro Obata, Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Research. ,vol. 58, pp. 2095- 2097 ,(1998)
H. Berg, Cold Spring Harbor Symposia on Quantitative Biology.: Vol. LII. Evolution of Catalytic Functions. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1987, ISBN 0-87969-054-2, xix + 955 pp., US $150.00. Journal of Electroanalytical Chemistry. ,vol. 276, pp. 417- 418 ,(1989) , 10.1016/0022-0728(89)87283-3
Miriam Cuatrecasas, Alberto Villanueva, Xavier Matias‐Guiu, Jaime Prat, None, K-ras mutations in mucinous ovarian tumors : A clinicopathologic and molecular study of 95 cases Cancer. ,vol. 79, pp. 1581- 1586 ,(1997) , 10.1002/(SICI)1097-0142(19970415)79:8<1581::AID-CNCR21>3.0.CO;2-T
David M. Gershenson, Charlotte C. Sun, Karen H. Lu, Robert L. Coleman, Anil K. Sood, Anais Malpica, Michael T. Deavers, Elvio G. Silva, Diane C. Bodurka, Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstetrics & Gynecology. ,vol. 108, pp. 361- 368 ,(2006) , 10.1097/01.AOG.0000227787.24587.D1
Hannah Farmer, Nuala McCabe, Christopher J. Lord, Andrew N. J. Tutt, Damian A. Johnson, Tobias B. Richardson, Manuela Santarosa, Krystyna J. Dillon, Ian Hickson, Charlotte Knights, Niall M. B. Martin, Stephen P. Jackson, Graeme C. M. Smith, Alan Ashworth, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature. ,vol. 434, pp. 917- 921 ,(2005) , 10.1038/NATURE03445
Gad Singer, Ie-Ming Shih, Alexander Truskinovsky, Haldun Umudum, Robert J. Kurman, Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). International Journal of Gynecological Pathology. ,vol. 22, pp. 37- 41 ,(2003) , 10.1097/00004347-200301000-00009
David R. Crotzer, Charlotte C. Sun, Robert L. Coleman, Judith K. Wolf, Charles F. Levenback, David M. Gershenson, Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecologic Oncology. ,vol. 105, pp. 404- 408 ,(2007) , 10.1016/J.YGYNO.2006.12.024
Cheng-Han Lee, David G Huntsman, Maggie C. U Cheang, Robin L Parker, Lindsay Brown, Paul Hoskins, Dianne Miller, C Blake Gilks, Assessment of Her-1, Her-2, and Her-3 Expression and Her-2 Amplification in Advanced Stage Ovarian Carcinoma International Journal of Gynecological Pathology. ,vol. 24, pp. 147- 152 ,(2005) , 10.1097/01.PGP.0000152026.39268.57
C. Blake Gilks, Jaime Prat, Ovarian carcinoma pathology and genetics: recent advances Human Pathology. ,vol. 40, pp. 1213- 1223 ,(2009) , 10.1016/J.HUMPATH.2009.04.017
Geoffrey D. Girnun, Elnaz Naseri, Scott B. Vafai, Lishu Qu, Jeffrey D. Szwaya, Roderick Bronson, John A. Alberta, Bruce M. Spiegelman, Synergy between PPARγ Ligands and Platinum-Based Drugs in Cancer Cancer Cell. ,vol. 11, pp. 395- 406 ,(2007) , 10.1016/J.CCR.2007.02.025